Ocera Therapeutics Inc (OCRX) : Vhcp Management scooped up 92,820 additional shares in Ocera Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 796,550 shares of Ocera Therapeutics Inc which is valued at $2.2 Million.Ocera Therapeutics Inc makes up approximately 2.00% of Vhcp Management’s portfolio.
Other Hedge Funds, Including , Group One Trading reduced its stake in OCRX by selling 1,346 shares or 24.47% in the most recent quarter. The Hedge Fund company now holds 4,154 shares of OCRX which is valued at $11,299.
Ocera Therapeutics Inc closed down -0.07 points or -2.69% at $2.53 with 19,275 shares getting traded on Wednesday. Post opening the session at $2.62, the shares hit an intraday low of $2.52 and an intraday high of $2.68 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Many Wall Street Analysts have commented on Ocera Therapeutics Inc. Brean Capital Initiated Ocera Therapeutics Inc on Feb 23, 2016 to “Buy”, Price Target of the shares are set at $10.
Ocera Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of a clinical candidate OCR-002 for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule ornithine phenylacetate which functions as an ammonia scavenger. In pre-clinical studies OCR-002 reduced arterial ammonia in an animal model of chronic liver disease and reduced arterial ammonia brain ammonia and intracranial pressure in a second animal model of acute liver failure. The Company has completed a Phase I pharmacokinetic and safety clinical trial of the intravenous form of OCR-002. A Phase IIa investigator-sponsored study in Spain tested OCR-002 in patients with upper gastrointestinal bleeding associated with liver cirrhosis. The Company is conducting a randomized placebo-controlled double blind Phase IIb clinical trial of OCR-002.